D. Western Therapeutics Institute, Inc. (TYO:4576)
99.00
-1.00 (-1.00%)
Mar 6, 2026, 3:30 PM JST
TYO:4576 Revenue
In the year 2025, D. Western Therapeutics Institute had annual revenue of 387.62M JPY, down -17.70%. D. Western Therapeutics Institute had revenue of 90.52M in the quarter ending December 31, 2025, a decrease of -25.85%.
Revenue
387.62M
Revenue Growth
-17.70%
P/S Ratio
13.86
Revenue / Employee
18.46M
Employees
21
Market Cap
5.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 387.62M | -83.38M | -17.70% |
| Dec 31, 2024 | 471.00M | 43.00M | 10.05% |
| Dec 31, 2023 | 428.00M | -20.00M | -4.46% |
| Dec 31, 2022 | 448.00M | 34.00M | 8.21% |
| Dec 31, 2021 | 414.00M | 59.00M | 16.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.89B |
| Linical | 9.32B |
| Kohjin Bio | 5.07B |
| Soiken Holdings | 4.58B |
| PRISM BioLab Co.,LTD | 684.61M |
| Chiome Bioscience | 593.29M |
| Carna Biosciences | 579.06M |
| Noile-Immune Biotech | 5.00M |